The German government “wants to hold talks” with the new US government to agree to a change in US policy prioritizing local supplies of the coronavirus vaccine at US production facilities, according to documents from the German health ministry.
In a lengthy document published Tuesday responding to inquiries from the German Social Democrats, the health ministry explained why the US could secure an additional supply of BioNTech / Pfizer vaccine for a certain date, whereas an increase in EU supply would come “in 2021.”
The health ministry stated that an executive order from the US president stated that production facilities in the country were “encouraged to provide vaccines for supply in the US”. This means that BioNTech / Pfizer vaccine production sites in Europe, as well as Moderna vaccines, need to supply worldwide, apart from Europe.
“The company as well as the federal government would like to hold talks with the new US government to reach an adjustment,” wrote the health ministry.
The document also discusses the bilateral agreement Germany has with BioNTech / Pfizer – something related to that The commission has let Germany escape, although it appears to be at odds with the block’s efforts to develop an integrated vaccine strategy.
The problem, the health ministry explained, was the funds BioNTech received from the German ministry of education and research. This cash means BioNTech will have to provide a portion of the vaccine to Germany. As a result, the health ministry had to issue a pre-contracted intention letter in the form of a memorandum of understanding on September 8 for an additional 30 million doses of vaccine, the health ministry wrote.